nach oben

Erschienen in:

01.11.2015 | Original Article

Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour

verfasst von: Caitriona Cahir, Stephan U. Dombrowski, Catherine M. Kelly, M. John Kennedy, Kathleen Bennett, Linda Sharp

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Five to 10 years of adjuvant hormonal therapy is recommended to prevent breast cancer recurrence. This study investigated modifiable influences on adjuvant hormonal therapy medication-taking behaviour (MTB) in women with stage I–III breast cancer.

Methods

Semi-structured face-to-face interviews among women with stage I–III breast cancer prescribed adjuvant hormonal therapy purposively sampled by their MTB at two cancer centres. Thematic analysis was conducted based on the Framework approach, with the Theoretical Domains Framework (TDF) informing the analysis framework; the TDF is an integrative framework consisting of 14 domains of behavioural change to inform intervention design.

Results

Thirty-one women participated in interviews (14 adherent/persistent; 7 non-adherent/persistent; 10 non-persistent). Three domains identified both barriers and enablers to hormonal therapy MTB across the three MTB strata: beliefs about consequences, intentions and goals and behaviour regulation, but their influence was different across the strata. Other domains influenced individual MTB strata. Key enablers for adherent/persistent women were identified within the domain beliefs about consequences (breast cancer recurrence), intentions and goals (high-priority), beliefs about capabilities (side effects) and behaviour regulation (managing medication). Barriers were identified within the domain behaviour regulation (no routine), memory, attention and decision processes (forgetting) and environmental context and resources (stressors) for non-adherent/persistent women and intentions and goals (quality of life), behaviour regulation (temporal self-regulation), reinforcement, beliefs about consequences (non-necessity) and social influences (clinical support) for non-persistent women.

Conclusion

This study identified modifiable influences on hormonal therapy MTB. Targeting these influences in clinical practice may improve MTB and hence survival in this population.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRefPubMed

Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497CrossRefPubMed

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCentralCrossRefPubMed

Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109(5):832–839CrossRefPubMed

Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer 109(6):1513–1521PubMedCentralCrossRefPubMed

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537PubMedCentralCrossRefPubMed

DiMatteo M, Giordani P, Lepper H, Croghan T (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40(9):794–811CrossRefPubMed

Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen ECG et al (2013) Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol 24(9):2324–2329CrossRefPubMed

10.

Gale N, Heath G, Cameron E, Rashid S, Redwood S (2013) Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 13(1):117PubMedCentralCrossRefPubMed

11.

Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A (2005) Making psychological theory useful for implementing evidence based practice: a consensus approach. Qual Saf Health Care 14(1):26–33PubMedCentralCrossRefPubMed

12.

Cane J, O’Connor D, Michie S (2012) Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci 7(37):1–17

13.

Michie S, Johnston M, Francis J, Hardeman W, Eccles M (2008) From theory to intervention: mapping theoretically derived behavioural determinants to behaviour change techniques. Appl Psychol 57(4):660–680CrossRef

14.

Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP et al (2010) What is an adequate sample size? operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229–1245CrossRefPubMed

15.

Ritchie J, Lewis J (2012) Qualitative research practice. SAGE Publications Ltd, London

16.

Francis JJ, Stockton C, Eccles MP, Johnston M, Cuthbertson BH, Grimshaw JM et al (2009) Evidence-based selection of theories for designing behaviour change interventions: using methods based on theoretical construct domains to understand clinicians' blood transfusion behaviour. Br J Health Psychol 14(4):625–646CrossRefPubMed

17.

McSherry L, Dombrowski SU, Francis JJ, Murphy J, Martin CM, O’Leary JJ (2012) 'It's a can of worms': understanding primary care practitioners' behaviours in relation to HPV using the theoretical domains framework. Implement Sci 7(1):73PubMedCentralCrossRefPubMed

18.

Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND (2007) Meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol 26(2):136CrossRefPubMed

19.

DiMatteo MR, Haskard KB, Williams SL (2007) Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 45(6):521–528CrossRefPubMed

20.

DiMatteo MR, Haskard-Zolnierek KB, Martin LR (2012) Improving patient adherence: a three-factor model to guide practice. Health Psychol Rev 6(1):74–91CrossRef

21.

Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47(6):555–567CrossRefPubMed

22.

Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315CrossRefPubMed

23.

Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220CrossRefPubMed

24.

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2014) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57(1):26–32PubMedCentralCrossRefPubMed

25.

Friese C, Pini TM, Li Y, Abrahamse P, Graff J, Hamilton A et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939PubMedCentralCrossRefPubMed

26.

Corter AL, Findlay M, Broom R, Porter D, Petrie KJ (2013) Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer. Br J Health Psychol 18(1):168–181CrossRefPubMed

27.

Leventhal H, Diefenbach M, Leventhal E (1992) Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cogn Ther Res 16(2):143–163CrossRef

28.

Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 27(31):5160–5167PubMedCentralCrossRefPubMed

29.

Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42(14):2271–2276CrossRefPubMed

30.

Arbuthnott A, Sharpe D (2009) The effect of physician–patient collaboration on patient adherence in non-psychiatric medicine. Patient Educ Couns 77(1):60–67CrossRefPubMed

31.

Arora NK, McHorney CA (2000) Patient preferences for medical decision making: who really wants to participate? Med Care 38(3):335–341CrossRefPubMed

32.

Trevino KM, Fasciano K, Prigerson HG (2013) Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer. J Clin Oncol 31(13):1683–1689CrossRefPubMed

33.

Lam WW, Kwok M, Chan M, Hung WK, Ying M, Or A et al (2014) Does the use of shared decision-making consultation behaviors increase treatment decision-making satisfaction among Chinese women facing decision for breast cancer surgery? Patient Educ Couns 94(2):243–249CrossRefPubMed

34.

Gollwitzer PM, Sheeran P. (2006) Implementation intentions and goal achievement: A Meta‐analysis of effects and processes. In: Mark PZ, editor. Advances in Experimental Social Psychology: Academic Press; p. 69-119

35.

Zimbardo PG, Boyd JN (1999) Putting time in perspective: a valid, reliable individual-differences metric. J Pers Social Psychol 77(6):1271–1288CrossRef

36.

Sansbury B, Dasgupta A, Guthrie L, Ward M (2014) Time perspective and medication adherence among individuals with hypertension or diabetes mellitus. Patient Educ Couns 95(1):104–110PubMedCentralCrossRefPubMed

37.

Manuel JC, Burwell SR, Crawford SL, Lawrence RH, Farmer DF, Hege A, Phillips K et al (2007) Younger women's perceptions of coping with breast cancer. Cancer Nurs 32(2):85–94CrossRef

38.

Pellegrini I, Sarradon-Eck A, Soussan PB, Lacour AC, Largillier R, Tallet A et al (2010) Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psychooncology 19(5):472–479CrossRefPubMed

39.

Nielsen-Bohlman LN, Panzar AM, Kindig DA (2004) Health literacy: a prescription to end confusion. National Academic Press, Washington DC

40.

Pass M, Belkora J, Moore D, Volz S, Sepucha K (2012) Patient and observer ratings of physician shared decision making behaviors in breast cancer consultations. Patient Educ Couns 88(1):93–99CrossRefPubMed

41.

Fowler FJ Jr, Gerstein BS, Barry MJ (2013) How patient centered are medical decisions? results of a national survey. JAMA 173(13):1215–1221

42.

Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14(6):612–616CrossRefPubMed

43.

Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103CrossRefPubMed

44.

Zolnierek KB, Dimatteo MR (2009) Physician communication and patient adherence to treatment: a meta-analysis. Med Care 47(8):826–834CrossRefPubMed

45.

Cane J, Richardson M, Johnston M, Ladha R, Michie S (2014) From lists of behaviour change techniques (BCTs) to structured hierarchies: comparison of two methods of developing a hierarchy of BCTs. Br J Health Psychol. doi:10.1111/bjhp.12102 PubMed

Titel: Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour
verfasst von: Caitriona Cahir
Stephan U. Dombrowski
Catherine M. Kelly
M. John Kennedy
Kathleen Bennett
Linda Sharp
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2685-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience

Professional oral health care reduces oral mucositis pain in patients treated by superselective intra-arterial chemotherapy concurrent with radiotherapy for oral cancer

The eating experience in long-term survivors of head and neck cancer: a mixed-methods study

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

Potential factors associated with perceived cognitive impairment in breast cancer survivors

A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie